What is NEUP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NEUP?

P/E (TTM) is n/a and 52-week range is $3.19 to $19.56 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NEUP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NEUP?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-490M, EPS (TTM) near $-5.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neuphoria Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Burlington, Massachusetts, US, 5.4M shares outstanding, ISIN US64136E1029 when available from company profile and filing metadata.

Neuphoria Therapeutics Inc

$NEUP

Health Care · Biotechnology

IR Run Scenarios

$3.36

+0.30%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 7 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Employees

Website

www.neuphoriatx.com/

IPO

1999-12-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)